An abuse liability comparison of flunitrazepam and triazolam in sedative drug abusers

Behavioural Pharmacology

Volumn 16, Issue 7, 2005, Pages 579-584

  Mintzer, Miriam Z ^a   Griffiths, R R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Abuse liability; Benzodiazepine; Flunitrazepam; Human; Hypnotic; Triazolam

Indexed keywords

FLUNITRAZEPAM; PLACEBO; SEDATIVE AGENT; TRIAZOLAM;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABUSE; DRUG COST; DRUG EFFECT; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; PSYCHOMOTOR PERFORMANCE; SCORING SYSTEM;

ADULT; ANTI-ANXIETY AGENTS; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FLUNITRAZEPAM; GENERALIZATION (PSYCHOLOGY); HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; PSYCHOMOTOR PERFORMANCE; QUESTIONNAIRES; SUBSTANCE-RELATED DISORDERS; TRIAZOLAM;

EID: 26244461768     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fbp.0000172736.11994.3c     Document Type: Article

References (20)

1. Barnas C, Rossmann M, Roessler H, Riemer Y, Fleischhacker WW (1992). Benzodiazepines and other psychotropic drugs abused by patients in a methadone maintenance program: Familiarity and preference. J Clin Psychopharmacol 12:397-402.
2. Darke SG, Ross JE, Hall WD (1995). Benzodiazepine use among injecting heroin users. Med J Aust 162:645-647.
3. de Wit H, Dudish S, Ambre J (1993). Subjective and behavioral effects of diazepam depend on its rate of onset. Psychopharmacology (Berl) 112: 324-330.
4. Farré M, Teran M-T, Roset PN, Mas M, Torrens M, Cami J (1998). Abuse liability of flunitrazepam among methadone-maintained patients. Psychopharmacology (Berl) 140:486-495.
5. Friedman H, Greenblatt DJ, Burstein ES, Harmatz JS, Shader RI (1986). Population study of triazolam pharmacokinetics. Br J Clin Pharmacol 22:639-642.
6. Gelkopf M, Bleich A, Hayward R, Bodner G, Adelson M (1999). Characteristics of benzodiazepine abuse in methadone maintenance treatment patients: a 1 year prospective study in an Israeli clinic. Drug Alcohol Depend 55: 63-68.
7. Griffiths RR, Weerts EM (1997). Benzodiazepine self-administration in humans and laboratory animals: Implications for problems of long-term use and abuse. Psychopharmacology (Berl) 134:1-37.
8. Griffiths RR, Bigelow G, Liebson I (1979). Human drug self-administration: Double-blind comparison of pentobarbital, diazepam, chlorpromazine and placebo. J Pharmacol Exp Ther 210:301-310.
9. Griffiths RR, Bigelow G, Liebson I, Kaliszak JE (1980). Drug preference in humans: Double-blind choice comparison of pentobarbital, diazepam and placebo. J Pharmacol Exp Ther 215:649-661.
10. Jochemsen R, van Boxtel CJ, Hermans J, Briemer DD (1983). Kinetics of five benzodiazepine hypnotics in healthy subjects. Clin Pharmacol Ther 34: 42-47.
11. Mattila MAK, Larni HM (1980). Flunitrazepam: A review of its pharmacological and therapeutic use. Drugs 20:353-374.
12. Mintzer MZ, Griffiths RR (1998). Flunitrazepam and triazolam: a comparison of behavioral effects and abuse liability. Drug Alcohol Depend 53:49-66.
13. Mumford GK, Evans SM, Fleishaker JC, Griffiths RR (1995). Alprazolam absorption kinetics affects abuse liability. Clin Pharmacol Ther 57: 356-365.
14. Navaratnam V, Foong K (1990). Opiate dependence - the role of benzodiazepines. Curr Med Res Opin 11:620-630.
15. Roset PN, Farre M, de la Torre R, Mas M, Menoyo E, Hernandez C, et al. (2001). Modulation of rate of onset and intensity of drug effects reduces abuse potential in healthy males. Drug Alcohol Depend 64:285-298.
16. San L, Tato J, Torrens M, Castillo C, Farré M, Cami J (1993). Flunitrazepam consumption among heroin addicts admitted for inpatient detoxification. Drug Alcohol Depend 32:281-286.
17. Saum CA, Inciardi JA (1997). Rohypnol misuse in the United States. Subst Use Misuse 32:723-731.
18. Smith KM (1999). Drugs used in acquaintance rape. J Am Pharm Assoc 39: 519-583.
19. Smith KM, Larive LL, Romanelli F (2002). Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and γ-hydroxybutyrate. Am J Health Syst Pharm 59:1067-1076.
20. Woods JH, Winger G (1997). Abuse liability of flunitrazepam. J Clin Psychopharmacol 17(suppl 2):1S-57S.